CRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock. Vertex ...
CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access ...
In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...
Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...
CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ...
In May 2025, the world celebrated the success of KJ, an infant who was treated with the world’s first personalized CRISPR gene editing therapy. KJ was born with severe carbamoyl phosphate synthetase 1 ...
CRISPR-Cas9 genome editing enzyme. [Artur Plawgo / iStock / Getty Images Plus] We need a patient-first approach for any variant in any patient, whomever, wherever they are. Each and every patient ...
A sales partner offered a ray of hope that this company couldn't for itself.
A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results